Immunotherapy for tuberculosis: Wave of the future or tilting at windmills?

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 2, 2003, Pages 142-143

  Barnes, Peter F ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; TUBERCULOSTATIC AGENT;

CYTOKINE PRODUCTION; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; T-LYMPHOCYTES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0042165884     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2305001     Document Type: Editorial

References (16)

1. Kaufman SHE. How can immunology contribute to the control of tuberculosis? Nature Rev Immunol 2001;1:20-30.
2. Toossi Z, Kleinhenz ME, Ellner JJ. Defective interleukin 2 production and responsiveness in human pulmonary tuberculosis. J Exp Med 1986;163:1162-1172.
3. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, Wallis RS, Edmonds K, Okwera A, Mugerwa R, et al. Depressed T-cell interferon-γ responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999;180:2069-2073.
4. Lienhardt C, Azzurri A, Amedel A, Fielding K, Sillah J, Sow OY, Bah B, Beneglano M, Diallo A, Manetti R, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002;32:1605-1613.
5. Vankayalapati R, Wizel B, Weis SE, Klucar P, Shams H, Samten B, Barnes PF. Serum cytokine concentrations do not parallel Mycobacterium tuberculosis-induced cytokine production in tuberculosis patients. Clin Infect Dis 2003;36:24-28.
6. O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC. Recombinant Mycobacterium BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994;62:2508-2514.
7. Brill KJ, Li Q, Larkin R, Canaday DH, Kaplan DR, Boom WH, Silver RF. Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms. Infect Immun 2001;69:1755-1765.
8. Johnson BJ, Bekker LG, Rickman R, Brown S, Lesser M, Ress S, Willcox P, Steyn L, Kaplan G. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuberc Lung Dis 1997;78:195-203.
9. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali JG, Jankus DD, Eisenach KD, Boom WH, Ellner JJ, et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:185-191.
10. Lin C-H, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003;33:626-638.
11. Valdez H, Mitsuyama R, Landay A, Sevin AD, Chan ES, Spritzler J, Kalams SA, Pollard RB, Fahey J, Fox L, et al. Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003;187:320-325.
12. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. Quantitative bacillary reponse to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 1993;147:958-961.
13. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-1515.
14. Yamada G, Shijubo N, Shigehara K, Okamura H, Kurimoto M, Abe S. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. Am J Respir Crit Care Med 2000;161:1786-1789.
15. Tsao TCY, Huang CC, Chiou W-K, Yang P-Y, Hsieh M-J, Tsao K-C. Levels of interferon γ and interleukin-2 receptor-α for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 2002;6:720-727.
16. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomized placebo-controlled trial. Lancet 2002;360:1050-1055.